1 / 7

Ewing Sarcoma Therapeutics, Clinical Trials, Results

Ewing Sarcoma Therapeutics, Clinical Trials, Results

NidhiNehani
Télécharger la présentation

Ewing Sarcoma Therapeutics, Clinical Trials, Results

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Estrogen Receptor-Positive (ER+) Breast Cancer Pipeline to Witness Huge R&D Investment in the Coming Years

  2. Estrogen Receptor-Positive Breast Cancer Pipeline Analysis According to a new research report “Estrogen Receptor-Positive (ER+) Breast Cancer Pipeline Analysis, 2017 - Clinical Trials & Results, Patent, Designation, Collaboration, and Other Developments” published by P&S Market Research, Estrogen Receptor-Positive (ER+) breast cancer currently exhibits a pipeline with 74 drug candidates. Access Report Overview: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis ER+ breast cancer pipeline offers novel therapeutic targets for the treatment of breast cancer The study analyzed that the estrogen receptor positive breast cancer pipeline comprises approximately 74 drug candidates in different stages of development.

  3. Estrogen Receptor-Positive Breast Cancer Pipeline Analysis Insights on pipeline analysis As per the findings of the research, a major share of ER+ breast cancer pipeline drug candidates are being developed to be administered by oral route.

  4. Estrogen Receptor-Positive Breast Cancer Pipeline Analysis Chemical Genomics-Based Discovery Platform for ER+ breast cancer drug development Chipscreen Biosciences, Ltd. is using chemo genomics approach for the development of their drug candidates in ER+ breast cancer. The approach connects small molecule structures to disease targets and therapeutic functions to accelerate the discovery process by effectively comparing the molecular profiles of successful drugs, failed drugs, and classical toxins.

  5. Estrogen Receptor-Positive Breast Cancer Pipeline Analysis Major companies collaborate for the development of ER+ breast cancer pipeline The research finds that different companies have collaborated for the development of ER+ breast cancer. In January 2016, Radius Health, Inc. entered in a worldwide clinical collaboration with Novartis Pharmaceuticals to evaluate the safety and efficacy of combining investigational agent RAD1901 with LEE011 for advanced breast cancer. Some of the key players developing drugs for Estrogen Receptor-Positive (ER+) breast cancer are Chipscreen Biosciences, Ltd., Eli Lilly & Company, Genentech, Inc., and others.

  6. Estrogen Receptor-Positive Breast Cancer Pipeline Analysis Download report sample at: https://www.psmarketresearch.com/market-analysis/estrogen-receptor-positive-breast-cancer-pipeline-analysis/report-sample

  7. GET IN TOUCH THANK YOU! For information regarding permissions and other queries Kindly write to: US/Canada Toll-Free: 1-888-778-7886

More Related